

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

SECTION 1. IDENTIFICATION

Product name : Oxfendazole / Oxytoclozanide Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 37 McCarville Street
Charlottetown, PE C1E 2A7
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1B
Specific target organ toxicity : Category 2 (Central nervous system)
- single exposure (Oral)
Specific target organ toxicity : Category 2 (Liver, Testis, Brain)
- repeated exposure

GHS label elements

Hazard pictograms	:
Signal Word	: Danger
Hazard Statements	: H360FD May damage fertility. May damage the unborn child. H371 May cause damage to organs (Central nervous system) if swallowed. H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.
Precautionary Statements	: Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version 4.0 Revision Date: 06/20/2025 SDS Number: 7942504-00010 Date of last issue: 04/14/2025
Date of first issue: 03/19/2021

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P308 + P311 IF exposed or concerned: Call a doctor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Oxcyclozanide	3,3',5,5',6-Pentachloro-2'-hydroxysalicylanilide	2277-92-1	$\geq 30 - < 60$ *
oxfendazole	No data available	53716-50-0	$\geq 10 - < 30$ *
Starch, oxidized	Tapioca Starch	65996-62-5	$\geq 10 - < 30$ *
Magnesium stearate	Octadecanoic acid, magnesium salt (2:1)	557-04-0	$\geq 1 - < 5$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
---	--

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

- | | |
|---|---|
| Environmental precautions | :
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | :
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

SECTION 7. HANDLING AND STORAGE

- | | |
|-----------------------------|---|
| Technical measures | :
Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | :
If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | :
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | :
Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations. |
| Materials to avoid | :
Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides |

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version 4.0 Revision Date: 06/20/2025 SDS Number: 7942504-00010 Date of last issue: 04/14/2025
Date of first issue: 03/19/2021

Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxcyclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Starch, oxidized	65996-62-5	TWA (Total particulates)	0.5 mg/m ³	CA AB OEL
		TWAEV (inhalable dust)	3 mg/m ³	CA QC OEL
		TWA (inhalable dust)	0.5 mg/m ³	CA BC OEL
		TWA (Total dust)	3 mg/m ³	CA ON OEL
		TWA (inhalable dust)	0.5 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA	10 mg/m ³	CA AB OEL
		TWA (Inhalable)	10 mg/m ³	CA BC OEL
		TWA (Respirable)	3 mg/m ³	CA BC OEL
		TWAEV (inhalable dust)	10 mg/m ³	CA QC OEL
		TWAEV (respirable aerosol fraction)	3 mg/m ³	CA QC OEL
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

Minimize open handling.

Personal protective equipment

- | | | |
|--------------------------|---|--|
| Respiratory protection | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type |
| Hand protection | : | |
| Material | : | Chemical-resistant gloves |
| Remarks | : | Consider double gloving. |
| Eye protection | : | Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- | | | |
|---|---|--|
| Appearance | : | powder |
| Color | : | white to off-white, light cream, cream |
| Odor | : | No data available |
| Odor Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	0.88 g/cm ³
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition	:	No hazardous decomposition products are known.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Oxytoclozanide:

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg
Target Organs: Central nervous system
Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
LD50 (Dog): 1,600 mg/kg
LD50 (sheep): 250 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Oxytoclozanide:

Remarks : Not classified due to lack of data.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

oxfendazole:

Species	: Rabbit
Result	: No skin irritation

Magnesium stearate:

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Oxytoclozanide:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

oxfendazole:

Species	: Rabbit
Result	: No eye irritation

Magnesium stearate:

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Oxytoclozanide:

Routes of exposure	: Dermal
Remarks	: Not classified due to lack of data.

Magnesium stearate:

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

Components:

Oxytetracycline:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

oxfendazole:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive

Magnesium stearate:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials
-----------------------	---

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

Carcinogenicity

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years
Symptoms : No adverse effects.
Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Symptoms : No adverse effects.
Target Organs : Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects., No effects on fertility.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 17 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.9 mg/kg body weight
Target Organs: Liver
Result: No effects on fertility.

Test Type: Fertility
Species: Mouse
Application Route: Oral
Duration of Single Treatment: 1 Months
Fertility: NOAEL: 750 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: positive, Fetal effects.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

	Test Type: Embryo-fetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-fetal toxicity.
	Test Type: Embryo-fetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.
	Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility	: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Oxcyclozanide:

Routes of exposure	: Oral
Target Organs	: Central nervous system
Assessment	: May cause damage to organs.

STOT-repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Components:

Oxcyclozanide:

Target Organs	: Brain, Liver
---------------	----------------

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version 4.0 Revision Date: 06/20/2025 SDS Number: 7942504-00010 Date of last issue: 04/14/2025
Date of first issue: 03/19/2021

Assessment : May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Routes of exposure : Oral
Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Oxcyclozanide:

Species : Rat
NOAEL : 9 mg/kg
LOAEL : 44.5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Brain, Liver, spleen, Adrenal gland
Symptoms : Liver effects

Species : Dog
NOAEL : 5 mg/kg
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Brain, Liver
Symptoms : blood effects, alteration in liver enzymes

oxfendazole:

Species : Rat
NOAEL : 11 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Target Organs : Blood, Liver, Testis

Species : Rat
NOAEL : 3.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver, Testis

Species : Mouse
NOAEL : 750 mg/kg
Application Route : Oral
Exposure time : 1 Months
Target Organs : Liver

Species : Mouse
NOAEL : 37.5 mg/kg
Application Route : Oral

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

Exposure time : 3 Months
Target Organs : Liver

Species : Dog
NOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 1 Months
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 11 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Target Organs : Lymph nodes, thymus gland

Species : Dog
NOAEL : 13.5 mg/kg
Application Route : Oral
Exposure time : 12 Months
Target Organs : Liver

Starch, oxidized:

Species : Rat
NOAEL : 22,500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

Oxclozanide:

Not applicable

Experience with human exposure

Components:

Oxclozanide:

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Oxytoclozanide:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.69 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	---	--

oxfendazole:

Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l Exposure time: 96 h LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.059 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.023 mg/l Exposure time: 21 d Method: OECD Test Guideline 211

Magnesium stearate:

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

	Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.
	NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

Components:

Oxclozanide:

Stability in water	: Hydrolysis: 50 %(156 d) Method: OECD Test Guideline 111
--------------------	--

oxfendazole:

Stability in water	: Hydrolysis: < 5 %(4 d)
--------------------	--------------------------

Magnesium stearate:

Biodegradability	: Result: Not biodegradable Remarks: Based on data from similar materials
------------------	--

Bioaccumulative potential

Components:

Oxclozanide:

Partition coefficient: n-octanol/water	: log Pow: 3.99 pH: 7 Method: OECD Test Guideline 107
--	---

oxfendazole:

Partition coefficient: n-octanol/water	: log Pow: 1.95
--	-----------------

Magnesium stearate:

Partition coefficient: n-octanol/water	: log Pow: > 4
--	----------------

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

Mobility in soil

Components:

Oxytoclozanide:

Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

oxfendazole:

Distribution among environmental compartments : log Koc: 3.2

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxytoclozanide)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(oxfendazole, Oxytoclozanide)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

	N.O.S. (oxfendazole, Oxyclozanide)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (oxfendazole, Oxyclozanide)
Class	: 9
Packing group	: III
Labels	: 9
ERG Code	: 171
Marine pollutant	: yes(oxfendazole, Oxyclozanide)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	: Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	: Canada. British Columbia OEL
CA ON OEL	: Ontario Table of Occupational Exposure Limits made under the Occupational Health and Safety Act.
CA QC OEL	: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	: 8-hour, time-weighted average

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA ON OEL / TWA	:	Time-Weighted Average Limit (TWA)
CA QC OEL / TWA EV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/20/2025
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
4.0	06/20/2025	7942504-00010	Date of first issue: 03/19/2021

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8